Last reviewed · How we verify
NCT06566807
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Phase 2 trial testing Orelabrutinib, obinutuzumab in Marginal Zone Lymphoma in 51 participants. Currently enrolling.
10 August 2026
Quick facts
| Lead sponsor | Huai'an First People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 25 August 2024 |
| Primary completion | 10 August 2026 |
| Estimated completion | 10 August 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Orelabrutinib, obinutuzumab — full drug profile →
Conditions studied
- Marginal Zone Lymphoma — all drugs for Marginal Zone Lymphoma →
Sponsor
Huai'an First People's Hospital
Who can join
18 and older, any sex, with Marginal Zone Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of Orelabrutinib combined with Obinutuzumab for previously untreated MZL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06566807
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Marginal Zone Lymphoma
Currently open trials in the same condition.
- NCT06796998 — Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · Phase 2 · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
- NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
- NCT06563596 — Epco, Zanu, Ritux for R/R FL or MZL · Phase 2 · recruiting
Other Huai'an First People's Hospital trials
Trials by the same sponsor.
- NCT07115550 — A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib · NA · not yet recruiting
- NCT06936488 — A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combine · NA · enrolling by invitation
- NCT06445257 — A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL · NA · recruiting
- NCT06328179 — Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. · NA · recruiting
- NCT03585530 — Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06566807 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huai'an First People's Hospital
- Last refreshed: 22 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06566807.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing